823782-74-7

Basic information

• Product Name: 4-(2-TRIFLUOROMETHYL-PHENOXY)-PIPERIDINE HYDROCHLORIDE
• Synonyms: 4-(2-TRIFLUOROMETHYL-PHENOXY)-PIPERIDINE HYDROCHLORIDE;4-[2-(TRIFLUOROMETHYL)PHENOXY]PIPERIDINE HCL
• CAS NO: 823782-74-7
• Molecular Formula: C12H15ClF3NO
• Molecular Weight: 281.7
• Mol File: 823782-74-7.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• Storage Temp.: Inert atmosphere,Room Temperature
• CAS DataBase Reference: 4-(2-TRIFLUOROMETHYL-PHENOXY)-PIPERIDINE HYDROCHLORIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(2-TRIFLUOROMETHYL-PHENOXY)-PIPERIDINE HYDROCHLORIDE(823782-74-7)
• EPA Substance Registry System: 4-(2-TRIFLUOROMETHYL-PHENOXY)-PIPERIDINE HYDROCHLORIDE(823782-74-7)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 823782-74-7(Hazardous Substances Data)

Usage

General Description

4-(2-Trifluoromethyl-phenoxy)-piperidine hydrochloride is a chemical compound that consists of a piperidine ring and a trifluoromethyl-substituted phenoxy group. It is commonly used in the synthesis of pharmaceuticals and other organic compounds. 4-(2-TRIFLUOROMETHYL-PHENOXY)-PIPERIDINE HYDROCHLORIDE is often used as a building block for the creation of various drug candidates and has potential applications in medicinal chemistry and drug development. The hydrochloride salt form of 4-(2-Trifluoromethyl-phenoxy)-piperidine is water-soluble and can be easily handled in laboratory settings.

Upstream product

• 444-30-4 2-(trifluoromethyl)phenol 
• 109384-19-2 t-butyl 4-hydroxy piperidine-1-carboxylate 
• 921605-76-7 tert-butyl 4-[2-(trifluoromethyl)phenoxy]-piperidine-1-carboxylate 
• 824390-04-7 4-(2-(trifluoromethyl)phenoxy)piperidine 

Downstream Products

• 944240-58-8 C₂₁H₂₂F₃N₃O₄ 
• 916889-36-6 N'-hydroxy-5-{4-[2-(trifluoromethyl)phenoxy]piperidin-1-yl}-1,3,4-thiadiazole-2-carboximidamide 

Relevant articles and documents

COMPOUNDS AND USES THEREOF

The present invention features compounds useful in the treatment of neurological disorders and primary brain cancer. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological disorders and primary brain cancer.

Development of a liver-targeted stearoyl-CoA desaturase (SCD) inhibitor (MK-8245) to establish a therapeutic window for the treatment of diabetes and dyslipidemia

The potential use of SCD inhibitors for the chronic treatment of diabetes and dyslipidemia has been limited by preclinical adverse events associated with inhibition of SCD in skin and eye tissues. To establish a therapeutic window, we embarked on designing liver-targeted SCD inhibitors by utilizing molecular recognition by liver-specific organic anion transporting polypeptides (OATPs). In doing so, we set out to target the SCD inhibitor to the organ believed to be responsible for the therapeutic efficacy (liver) while minimizing its exposure in the tissues associated with mechanism-based SCD depletion of essential lubricating lipids (skin and eye). These efforts led to the discovery of MK-8245 (7), a potent, liver-targeted SCD inhibitor with preclinical antidiabetic and antidyslipidemic efficacy with a significantly improved therapeutic window.